Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib

Autor: Christine Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Nastya Kassir, Yuan Chen

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 4, Pp 660-672 (2024)

Abstract Pralsetinib, a potent and selective inhibitor of oncogenic RET fusion and RET mutant proteins, is a substrate of the drug metabolizing enzyme CYP3A4 and a substrate of the efflux transporter P‐gp based on in vitro data. Therefore, its phar

Externí odkaz: https://doaj.org/article/53d6ae92cc93495eba3b71ab9438d4b9

Concentration QTc analysis of giredestrant: Overcoming QT/heart rate confounding in the presence of drug‐induced heart rate changes

Autor: Logan Brooks, Michael Dolton, Jurgen Langenhorst, Kenta Yoshida, Yi Ting (Kayla) Lien, Vikram Malhi, Chunze Li, Pablo Perez‐Moreno, John Bond, Ya‐Chi Chen, Jiajie Yu

Publikováno v: Clinical and Translational Science, Vol 16, Iss 5, Pp 823-834 (2023)

Abstract Concentration‐QTc (C‐QTc) analysis has become a common approach for evaluating proarrhythmic risk and delayed cardiac repolarization of oncology drug candidates. Significant heart rate (HR) change has been associated with certain classes

Externí odkaz: https://doaj.org/article/309c621807754593873a9d5a3f1647b8

Population repeated time‐to‐event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires

Autor: Robin J Svensson, Jakob Ribbing, Naoki Kotani, Michael Dolton, Shweta Vadhavkar, Dorothy Cheung, Tracy Staton, David F Choy, Wendy Putnam, Jin Jin, Nageshwar Budha, Mats O. Karlsson, Angelica Quartino, Rui Zhu

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1221-1235 (2021)

Abstract Identification of covariates, including biomarkers, spirometry, and diaries/questionnaires, that predict asthma exacerbations would allow better clinical predictions, shorter phase II trials and inform decisions on phase III design, and/or i

Externí odkaz: https://doaj.org/article/99d33c6d1f7e4cdfb4ba2b342953726c

Belvarafenib penetrates the BBB and shows potent antitumor activity in a murine melanoma brain metastasis model

Autor: Yu-Yon Kim, Hyunjin Park, Taehun Song, Kyungjin Choi, Michael Dolton, Jialin Mao, Jisook Kim, Young Gil Ahn, Kwee Hyun Suh, Young Hoon Kim

Publikováno v: Clinical & Experimental Metastasis. 40:137-148

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0c10f4705273e94a03fe0dfd184bebd0
https://doi.org/10.1007/s10585-023-10198-7

Safety and Efficacy of Semorinemab in Individuals with Prodromal to Mild Alzheimer Disease

Autor: Edmond, Teng, Paul T, Manser, Karen, Pickthorn, Flavia, Brunstein, Mira, Blendstrup, Sandra, Sanabria Bohorquez, Kristin R, Wildsmith, Bali, Toth, Michael, Dolton, Vidya, Ramakrishnan, Ashwini, Bobbala, Sietske A M, Sikkes, Michael, Ward, Reina N, Fuji, Geoffrey A, Kerchner, David, Weisman

Publikováno v: JAMA Neurology, 79(8), 758-767. American Medical Association
Teng, E, Manser, P T, Pickthorn, K, Brunstein, F, Blendstrup, M, Sanabria Bohorquez, S, Wildsmith, K R, Toth, B, Dolton, M, Ramakrishnan, V, Bobbala, A, Sikkes, S A M, Ward, M, Fuji, R N & Kerchner, G A 2022, ' Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease : A Randomized Clinical Trial ', JAMA Neurology, vol. 79, no. 8, pp. 758-767 . https://doi.org/10.1001/jamaneurol.2022.1375
Teng, E, Manser, P T, Pickthorn, K, Brunstein, F, Blendstrup, M, Sanabria Bohorquez, S, Wildsmith, K R, Toth, B, Dolton, M, Ramakrishnan, V, Bobbala, A, Sikkes, S A M, Ward, M, Fuji, R N & Kerchner, G A 2022, ' Safety and Efficacy of Semorinemab in Individuals with Prodromal to Mild Alzheimer Disease : A Randomized Clinical Trial ', JAMA Neurology, vol. 79, no. 8, pp. 758-767 . https://doi.org/10.1001/jamaneurol.2022.1375

Importance: Neurofibrillary tangles composed of aggregated tau protein are one of the neuropathological hallmarks of Alzheimer disease (AD) and correlate with clinical disease severity. Monoclonal antibodies targeting tau may have the potential to am

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5221ef4dd6e70490909446ed6b1ce80
http://www.scopus.com/inward/record.url?scp=85132835366&partnerID=8YFLogxK